Literature DB >> 33413627

Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale.

Sunghee Hwang1, Jee Eun Chung1, Kwanghee Jun2, Young-Mi Ah3, Kwang-Il Kim4, Ju-Yeun Lee5.   

Abstract

BACKGROUND: Considering the limited generalizability of previous anticholinergic burden scales, the Korean Anticholinergic Burden Scale (KABS) as a scale specific to the Korean population was developed. We aimed to validate the KABS by detecting the associations between high anticholinergic burden, measured with the KABS, and emergency department (ED) visits compared to the pre-existing validated scales in older Korean adults.
METHODS: A nested case-control study was conducted using national claims data. The cases included the first anticholinergic ED visits between July 1 and December 31, 2016. Anticholinergic ED visits were defined as ED visits with a primary diagnosis of constipation, delirium, dizziness, fall, fracture, or urinary retention. Propensity score-matched controls were identified. Average daily AB scores during 30 days before the index date were measured. Multivariate logistic regression analyses were performed.
RESULTS: In total, 461,034 were included. The highest proportion of those with high AB was identified with KABS (5.0%). Compared with those who had a KABS score of 0, older adults with a score ≥ 3 were at higher risk for overall anticholinergic ED visits (aOR, 1.62, 95% CI, 1.53-1.72), as well as visits for falls/fractures (aOR: 1.54, 95% CI: 1.40-1.69), dizziness (aOR: 1.44, 95% CI: 1.30-1.59), delirium (aOR: 2.96, 95% CI: 2.28-3.83), constipation (aOR: 1.84, 95% CI: 1.68-2.02), and urinary retention (aOR: 2.13, 95% CI: 1.79-2.55). High AB by KABS showed a stronger association with overall anticholinergic ED visits and visits due to delirium and urinary retention than those by other scales.
CONCLUSIONS: In conclusion, KABS is superior to pre-existing scales in identifying patients with high AB and predicting high AB-related ED visits in older Korean adults.

Entities:  

Keywords:  Anticholinergic syndromes; Cholinergic antagonists; Emergency medical services; Geriatrics

Mesh:

Substances:

Year:  2021        PMID: 33413627      PMCID: PMC7792041          DOI: 10.1186/s40360-020-00467-6

Source DB:  PubMed          Journal:  BMC Pharmacol Toxicol        ISSN: 2050-6511            Impact factor:   2.483


  25 in total

1.  Development of an Anticholinergic Burden Scale specific for Korean older adults.

Authors:  Kwanghee Jun; Sunghee Hwang; Young-Mi Ah; Yewon Suh; Ju-Yeun Lee
Journal:  Geriatr Gerontol Int       Date:  2019-04-29       Impact factor: 2.730

2.  Comparative Associations Between Measures of Anti-cholinergic Burden and Adverse Clinical Outcomes.

Authors:  Wen-Han Hsu; Yu-Wen Wen; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  Ann Fam Med       Date:  2017-11       Impact factor: 5.166

Review 3.  Anticholinergics: theoretical and clinical overview.

Authors:  Prasad S Nishtala; Mohammed Saji Salahudeen; Sarah N Hilmer
Journal:  Expert Opin Drug Saf       Date:  2016-03-30       Impact factor: 4.250

4.  Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures.

Authors:  Lisa G Pont; Johannes T H Nielen; Andrew J McLachlan; Danijela Gnjidic; Lewis Chan; Robert G Cumming; Katja Taxis
Journal:  Br J Clin Pharmacol       Date:  2015-07-06       Impact factor: 4.335

5.  Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.

Authors:  Luca Pasina; Codjo D Djade; Ugo Lucca; Alessandro Nobili; Mauro Tettamanti; Carlotta Franchi; Francesco Salerno; Salvatore Corrao; Alessandra Marengoni; Alfonso Iorio; Maura Marcucci; Francesco Violi; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2013-02       Impact factor: 3.923

Review 6.  Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?

Authors:  Tanja Mayer; Walter E Haefeli; Hanna M Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-09-08       Impact factor: 2.953

7.  DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities.

Authors:  Nagham Ailabouni; Dee Mangin; Prasad S Nishtala
Journal:  Int J Clin Pharm       Date:  2019-01-18

8.  The anticholinergic risk scale and anticholinergic adverse effects in older persons.

Authors:  James L Rudolph; Marci J Salow; Michael C Angelini; Regina E McGlinchey
Journal:  Arch Intern Med       Date:  2008-03-10

9.  Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs.

Authors:  R M Leipzig; R G Cumming; M E Tinetti
Journal:  J Am Geriatr Soc       Date:  1999-01       Impact factor: 5.562

10.  "How much will I get charged for this?" Patient charges for top ten diagnoses in the emergency department.

Authors:  Nolan Caldwell; Tanja Srebotnjak; Tiffany Wang; Renee Hsia
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.